CD19 and acute lymphoblastic leukemia: Coincidentally, a phase 1 trial of CD19/22 sequential infusion of CAR‐T therapy on recurrent or refractory B‐ALL was demonstrated with a CR rate of 95.2% and a two year OS of 77.6%, compared to patients who received CD19 CAR‐T therapy achieving a CR rate of 83.0% and a two year OS of 77.6%, respectively (p = 0.006; p = 0.0187) [40].